A Study of Inebilizumab Efficacy and Safety in IgG4- Related Disease
NCT04540497
·
clinicaltrials.gov ↗
PHASE3
Phase
ACTIVE_NOT_RECRUITING
Status
135
Enrollment
INDUSTRY
Sponsor class
Conditions
IgG4 Related Disease
Interventions
DRUG:
Inebilizumab
OTHER:
Placebo
Sponsor
Amgen